Lilly’s Retevmo Shows Superior Survival in Phase III Thyroid Cancer Trial

Eli Lilly has scored a win against its competitors in the narrow but focused space of rearranged during transfection (RET)-mutant medullary thyroid cancer. The drugmaker announced topline results Tuesday showing that Retevmo (selpercatinib), its FDA-approved RET kinase inhibitor, beat out Exelixis’ Capometyx (cabozantinib) and Sanofi’s Caprelsa (vandetanib) in progression-free survival based on late-stage clinical trial results.